Table 1. Patient Characteristics.

ID	Age	Gender	Clinical TNM Stage	Induction C/T	Concurrent C/T	Pathologic Response	Pre-TMT FAM84B IHC Intensity	Post-TMT FAM84B IHC Intensity
Microarray & RT-PCR
316	48	M	T3N1M1b	None	DP	CR	2+	NA
833	62	M	T2N1M0	None	TP	CR	2+	NA
743	42	M	T3N1M1a	None	TP	nCR	NA	NE
040	52	M	T3N1M0	None	DP	nCR	NA	2+
843	45	M	T3N1M1b	TP-HDFL	TP	nCR	3+	3+
146	63	M	T3N0M1a	TP-HDFL	TP	CR	2+	NA
690	55	M	T3N1M0	None	DP	CR	2~3+	NA
817	48	M	T1N1M1a	TP-HDFL	TP	CR	2~3+	NA
153	47	M	T3N1M0	TP-HDFL	TP	CR	NA	NA
694	54	M	T3N1M0	None	PF	nCR	2+	3+
995	53	M	T3N1M0	TP-HDFL	TP	CR	1+	NA
450	49	M	T3N1M1a	TP-HDFL	TP	nCR	3+	2~3+
970	45	M	T3N1M0	None	TP	CR	0	NA
554	64	M	T3N1M0	TP-HDFL	TP	CR	NA	NA
809	52	M	T3N1M1a	None	PF	nCR	2+	2+
490	65	M	T4N1M1b	None	PF	nCR	3+	3+
618	56	M	T3N1M0	TP-HDFL	TP	nCR	1~2+	3+
193	51	M	T3N1M0	None	TP	CR	2~3+	NA
967	62	M	T3N1M0	TP-HDFL	TP	nCR	2+	2+
825	70	M	T3N1M0	TP-HDFL	TP	nCR	2~3+	2+
210	64	M	T3N1M0	None	PF	nCR	2+	2+
RT-PCR only
067	50	M	T3N1M1b	TP-HDFL	PF	nCR	2+	2+
906	74	M	T3N1M0	None	TP	CR	NA	NA
609	50	M	T3N1M0	TP-HDFL	TP	nCR	2+	NE
887	48	M	T3N1M0	None	DP	nCR	2+	3+
951	55	F	T3N1M0	None	TP	nCR	2+	1~2+
486	50	M	T3N0M0	TP-HDFL	TP	CR	3+	NA
557	70	M	T3N1M0	None	TP	nCR	3+	2~3+
085	37	M	T3N1M0	None	DP	nCR	2~3+	NE
834	50	M	T3N1M0	None	CTP	nCR	0~1+	2+
181	49	M	T3N1M0	None	CTP	CR	2+	NA
890	63	M	T3N1M0	None	CTP	CR	2+	NA
532	37	M	T3N0M0	None	CTP	nCR	2~3+	NE
141	64	M	T3N1M0	None	TP	CR	1~2+	NA
847	40	M	T3N1M0	None	CTP	nCR	1+	2+
632	47	M	T3N1M0	None	CTP	CR	0	NA
565	47	M	T3N1M0	None	CTP	nCR	1+	2+

Abbreviations: C/T, chemotherapy; TMT, tri-modality therapy, IHC, immunohistochemistry; M, male; F, female; CR, complete response; nCR, non-complete response; NA, not available; NE: not evaluable.

Chemotherapy regimens: TP-HDFL, paclitaxel (80 mg/m²) on days 1 and 8, cisplatin (35 mg/m²) on days 2 and 9, fluorouracil (2000 mg/m²) and leucovorin (300 mg/m²) on days 2 and 9; PF, cisplatin (30 mg/m²) and fluorouracil (425 mg/m²) once weekly; TP, paclitaxel (35 mg/m²) on days 1 and 4 of each week and cisplatin (15 mg/m²) on days 2 and 5 of each week; DP, docetaxel (20 mg/m²) and cisplatin (20 mg/m²) once weekly; CTP, cetuximab (400 mg/m²) on week -1 and (250 mg/m²) once weekly, paclitaxel (35 mg/m²) on days 1 and 4 of each week and cisplatin (15 mg/m²) on days 2 and 5 of each week.